Drugmakers leery of generic rival in trade group
Pharmaceutical lobbyists oppose Teva's move to join the Pharmaceutical Research and Manufacturers of America, saying that it is tantamount to allowing a spy into the fold
Washington
FOR decades, brand-name and generic drug companies have fought each other in Congress, at international trade negotiations and in court. So when the world's largest generic drug company moved this year to join the powerful trade association for producers of brand-name medicines, pharmaceutical lobbyists were in a swivet.
The trade group, the Pharmaceutical Research and Manufacturers of America, known as PhRMA, is plunging into battles over drug prices here and in many state capitols. And the request from the generic company, Teva Pharmaceutical Industries, is raising eyebrows in PhRMA's secretive councils.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue